Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Oncology Vol 33 No 1
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.
In this case, we examine a 49-year-old man with widespread metastatic sclerotic bone lesions. What is your diagnosis?
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
2
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma
5
